TY - JOUR
T1 - Expressions of p53, p63 and PIM1 proteins in nodal or extranodal diffuse large B-cell lymphoma and their prognostic significance
AU - Chen, Shu
AU - Xu, Xiaoying
AU - Lei, Yuanyuan
AU - Huang, Pu
AU - Yang, Xin
AU - Liu, Yanxue
AU - Guo, Yuhong
AU - Zhang, Yanhui
AU - Pan, Yi
AU - Zhai, Qiongli
AU - Wang, Xianhuo
AU - Li, Lanfang
AU - Zhang, Huilai
AU - Fu, Kai
AU - Meng, Bin
N1 - Publisher Copyright:
© 2019 by TUMOR.
PY - 2019
Y1 - 2019
N2 - Objective: To investigate the correlation between the expression of p53, p63 or PIM1 protein and the survival of patients with nodal or extranodal diffuse large B-cell lymphoma (DLBCL). Methods: Immunohistochemical staining was applied to examine the expressions of p53, p63 and PIM1 proteins in nodal or extranodal DLBCL. The differences in the expressions of p53, p63 and PIM1 proteins between nodal and extranodal DLBCL were analyzed by χ2 test. Kaplan-Meier survival curve and COX proportional hazard model were used to analyze the relationship between the clinicopathological factors (including p53, p63 and PIM1 expressions) and the prognosis of patients with nodal or extranodal DLBCL. Results: Among 212 DLBCL cases, there were 101 nodal cases and 111 extranodal cases (including 55 cases of gastrointestinal DLBCL and 56 cases of non-gastrointestinal DLBCL). The expression rates of p53, p63 and PIM1 proteins in all cases were 19.0%, 25.2% and 54.7%, respectively. Among them, p53 was expressed more frequently in extranodal gastrointestinal cases (P < 0.05), p63 was expressed more commonly in extranodal non-gastrointestinal cases (P < 0.05), whereas PIM1 expression was not significant among the three groups (all P > 0.05). Much more p53-positive cases were observed with international prognostic index (IPI) ≥ 3 (P < 0.05), while p63-positive patients were more common with elevated lactate dehydrogenase (LDH) (P < 0.05). However, PIM1 expression was not significantly correlated with the clinicopathological factors (all P > 0.05). Survival analysis showed that the expression of p53 or p63 protein was a significant inferior prognostic factor for overall survival (OS) and progression-free survival (PFS) in nodal patients or extranodal non-gastrointestinal DLBCL patients, respectively (both P < 0.05), while PIM1 expression was an inferior prognostic factor for PFS in extranodal gastrointestinal cases (P < 0.05). Conclusion: The molecular mechanisms of DLBCL pathogenesis may be different between different locations of DLBCL, which is worth further exploration.
AB - Objective: To investigate the correlation between the expression of p53, p63 or PIM1 protein and the survival of patients with nodal or extranodal diffuse large B-cell lymphoma (DLBCL). Methods: Immunohistochemical staining was applied to examine the expressions of p53, p63 and PIM1 proteins in nodal or extranodal DLBCL. The differences in the expressions of p53, p63 and PIM1 proteins between nodal and extranodal DLBCL were analyzed by χ2 test. Kaplan-Meier survival curve and COX proportional hazard model were used to analyze the relationship between the clinicopathological factors (including p53, p63 and PIM1 expressions) and the prognosis of patients with nodal or extranodal DLBCL. Results: Among 212 DLBCL cases, there were 101 nodal cases and 111 extranodal cases (including 55 cases of gastrointestinal DLBCL and 56 cases of non-gastrointestinal DLBCL). The expression rates of p53, p63 and PIM1 proteins in all cases were 19.0%, 25.2% and 54.7%, respectively. Among them, p53 was expressed more frequently in extranodal gastrointestinal cases (P < 0.05), p63 was expressed more commonly in extranodal non-gastrointestinal cases (P < 0.05), whereas PIM1 expression was not significant among the three groups (all P > 0.05). Much more p53-positive cases were observed with international prognostic index (IPI) ≥ 3 (P < 0.05), while p63-positive patients were more common with elevated lactate dehydrogenase (LDH) (P < 0.05). However, PIM1 expression was not significantly correlated with the clinicopathological factors (all P > 0.05). Survival analysis showed that the expression of p53 or p63 protein was a significant inferior prognostic factor for overall survival (OS) and progression-free survival (PFS) in nodal patients or extranodal non-gastrointestinal DLBCL patients, respectively (both P < 0.05), while PIM1 expression was an inferior prognostic factor for PFS in extranodal gastrointestinal cases (P < 0.05). Conclusion: The molecular mechanisms of DLBCL pathogenesis may be different between different locations of DLBCL, which is worth further exploration.
KW - Diffuse
KW - Immunohistochemistry
KW - Large B-cell
KW - Location of disease
KW - Lymphoma
KW - P63 protein
KW - PIM1 protein
KW - Prognosis
KW - Tumor suppressor protein p53
UR - http://www.scopus.com/inward/record.url?scp=85078171431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078171431&partnerID=8YFLogxK
U2 - 10.3781/j.issn.1000-7431.2019.33.511
DO - 10.3781/j.issn.1000-7431.2019.33.511
M3 - Article
AN - SCOPUS:85078171431
SN - 1000-7431
VL - 39
SP - 931
EP - 941
JO - Tumor
JF - Tumor
IS - 11
M1 - 1000-7431 (2019) 11-0931-11
ER -